Analyst Reco. Can-Fite BioPharma Ltd.

Equities

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:53 2025-07-09 am EDT			5-day change	1st Jan Change
1.200 ^ILa	-7.69%		-7.69%	-36.84%

Jun. 16	Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston	CI
May. 05	Can-Fite Says It Has Raised $175 Million To Date For Development Of Namodenoson And Piclidenoson	RE

HC Wainwright Adjusts Can-Fite Biopharma Price Target to $18 From $34, Maintains Buy Rating	23-10-24	MT
CAN FITE BIOPHARMA : Aegis Capital Starts Can-Fite Biopharma at Buy with $5 Price Target	21-06-24	MT

No results for this search